VolitionRx Reports >99% Tumor DNA Purity With ‘Capture-Seq’

Overview

• The company said two blinded cohorts showed detection of 49 of 49 cancers in one set and 13 of 14 in another.
• Capture-Seq uses physical enrichment followed by bioinformatics to isolate circulating tumor DNA at greater than 99% purity.
• The approach targets CTCF‑bound fragments that the company says are scarce in healthy plasma and enriched in cancer patients.
• VolitionRx noted that the method captures only a subset of ctDNA, so missed cancer fragments remain possible and broader validation is required.
• VNRX shares jumped more than 70% in pre‑market trading as the firm submitted an updated preprint to Research Square and engaged potential licensing partners for a market it estimates at about $36 billion.